Galmed Pharmaceuticals Ltd expected to post a loss of 34 cents a share - Earnings Preview

Eocene

31/07/2023 19:35

* Galmed Pharmaceuticals Ltd  GLMD.OQ   GLMD.O  is expected
to show no change in quarterly revenue when it reports 
results on August 2 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Galmed
Pharmaceuticals
Ltd is for a loss of 34 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".​
    * Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $4​, above​ its last closing price
of $1.19. ​​​

This summary was machine generated July 31 at 18:34 GMT.  All
figures in US dollars  unless otherwise stated